Cellivery Applies for FDA IND for Phase 1 Clinical Trial of COVID-19 Immune Therapy
[Asia Economy Reporter Minji Lee] Cellivery announced on the 13th that it has submitted an Investigational New Drug (IND) application for the Phase 1 clinical trial of the COVID-19 immune therapeutic iCP-NI to the U.S. Food and Drug Administration (FDA).
Hot Picks Today
!["It Has Now Crossed Borders": No Vaccine or Treatment as Bundibugyo Ebola Variant Spreads [Reading Science]](https://cwcontent.asiae.co.kr/asiaresize/93/2026052019230771274_1779272587.jpg)
"It Has Now Crossed Borders": No Vaccine or Treatment as Bundibugyo Ebola Variant Spreads [Reading Science]
- "Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Even With a 90 Million Won Salary and Bonuses, It Doesn’t Feel Like Much"... A Latecomer Rookie Who Beat 70 to 1 Odds [Scientists Are Disappearing] ③
- "Am I Really in the Top 30%?" and "Worried About My Girlfriend in the Bottom 70%"... Buzz Over High Oil Price Relief Fund
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
The company stated, "Based on non-clinical trial (safety evaluation) results, GLP-level toxicity tests of iCP-NI confirmed that effective drug concentrations are reached at low doses," adding, "We expect the development of a COVID-19 immune therapeutic that can demonstrate efficacy against various inflammatory diseases without causing toxicity."
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
